Skip to main content

Roche testing for coronavirus and flu simultaneously

| News

Roche testing for coronavirus and flu simultaneously

04.09.2020

The U.S. Food and Drug Administration has given the Basel-based life sciences company Roche authorization to use a test that simultaneously tests for the coronavirus and flu infections. Roche is also launching a rapid antigen test for coronavirus.

Roche has developed a testing process for the simultaneous qualitative detection and differentiation of SARS-CoV-2, Influenza A and Influenza B in patients. This can be done with a single sample. According to a press release, the U.S. Food and Drug Administration (FDA) has authorized Roche to use this test in laboratories with the relevant certification. It has done so through Emergency Use Authorization, which means final authorization and approval have not yet been granted.

“With the approaching flu season, this new test is particularly important as SARS-CoV-2 and influenza infections can hardly be differentiated by symptoms alone. Now, with a single test, healthcare professionals can confidently provide the right diagnosis and most effective treatment plan for their patients,” said Thomas Schinecker, CEO of Roche Diagnostics.

The test is carried out with Roche’s widely-available, fully-automated cobas 6800/8800 systems, which provide up to 96 results in just three hours. Roche is thereby expanding its portfolio to include solutions for the fight against COVID-19. As recently as 1 September, a rapid antigen test for coronavirus had been announced. It will be launched at the end of this month. Roche intends to apply to the FDA for Emergency Use Authorization for this test as well.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

The power of a persuasive pitch deck

Are you an entrepreneur striving to secure investment for your biotech startup? Start with an effective pitch deck to catch...
Read More

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

How to access the U.S. market with your medical device

In one of our latest Venture Mentoring events by Basel Are Business & Innovation, we invited Nila-Pia Rähle to speak...
Read More

Do you have a question? We'd like to hear from you.